Yan CV, 2-15-2020

1

CURRICULUM VITAE

Jun Yan, M.D., Ph.D. Home address: 305 Longview Park Place, Louisville, KY 40245

Tel: (502) 852-3628 (O), (502) 852-7168 (L) 852-5357 (L) Fax: (502) 852-2123

Email: jun.yan@louisville.edu

EDUCATION 07/1997: Ph. D. - Immunology - Shanghai Institute of Immunology, Shanghai Jiaotong University School of Medicine 07/1991: M. S. - Immunology - Department of Microbiology and Immunology, Nanjing Medical University 07/1985: M.D. – Jiangsu University School of Medicine

ACADEMIC APPOINTMENTS 08/1997 ~ 01/1999: Postdoctoral Fellow, Department of Pathology, University of Louisville, Louisville, KY 02/1999 ~ 01/2002: Research Associate, Department of Internal Medicine, Yale University, New Haven, CT 02/2002 ~ 12/2002: Associate Research Scientist – Section of Rheumatology, Department of Internal Medicine, Yale University, New Haven, CT 01/2003 ~ 06/2008: Assistant Professor, James Graham Brown Cancer Center, Department of Medicine, University of Louisville, Louisville, KY 07/2008 ~ 06/2012: Associate Professor with tenure, James Graham Brown Cancer Center, Department of Medicine, University of Louisville, Louisville, KY 2011~2019: Co-Director, Tumor Immunobiology Program, James Graham Brown Cancer Center, University of Louisville, Louisville, KY 03/2012~ present: Endowed Chair in Translational Research, James Graham Brown Cancer Center, University of Louisville, Louisville, KY 07/2012~ 2019: Professor of Medicine, Director of Tumor Immunobiology Program, James Graham Brown Cancer Center, University of Louisville, Louisville, KY

Yan CV, 2-15-2020

2

07/2019 – present: Professor of Surgery, Director, Division of Immunotherapy, University of Louisville School of Medicine

PROFESSIONAL MEMBERSHIPS AND ACTIVITIES

1997, Clinical Immunology Society 2000, American Association of Immunologists 2003, American Association for Cancer Research 2003, Research Member of American College of Rheumatology 2014, American Society of Hematology

HORNORS and AWARDS

1996: Third prize winner of dissertation in The Advanced Course and Symposium in Immunology organized by IUIS. Beijing, China 1998: New Investigators Award by CIS (Clinical Immunology Society) 2002-2006: Career Development Award, S.L.E Foundation 2003: AAI Junior Faculty Travel Award 2003-2009: American College of Rheumatology Investigator Award 2003: Roger Herzig Junior Faculty Research Prize (University of Louisville) 2006: NIH TTT study section ad hoc member 2008: Reviewer, Arthritis Foundation Clinical Immunology Study Section 2008: Outstanding Investigator Award, Department of Medicine, University of Louisville 2009: NIH TTT study section ad hoc member, NIH CII study section ad hoc member 2009-2013: American Cancer Society Research Scholar Grant 2010: DOD IMM-1 study section member 2010: NIH RC4 study section member 2010: Julep Ball Scientist of the Year, James Graham Brown Cancer Center, University of Louisville 2011: Grant Reviewer, Association for International Cancer Research, UK 2012: Grant Reviewer, Austria Science Fund 2013: Reviewer, Hollings Cancer Center Pilot Project 2013: Reviewer, Czech Science Foundation 2014: Reviewer, National Psoriasis Foundation 2014: NIH/NIDCR Special Emphasis Panel ZDE1VH07 study section member 2010-2014: Regular member, NIH TTT study section 2015: NIH CII study section 2015: National Psoriasis Foundation 2015: Ad hoc NIH CII Study Section 2015: Grant Reviewer, NIH ZRG1 F07-S Study Section 2016: FDA site visit Reviewer 2016: NIH study sections: ZRG1 BCMB-A, ZRG1 OCT-XX(55), CII, IMMU02, NSFC 2017: NIH study section: ZRG1 OCT (55), TTT, ZRG1 OTC-K (02) M, ZRG1 OTC (55), NSFC

Yan CV, 2-15-2020

3

2018: NIH/NCI SPORE (1/25/18), ZRG OTC-X (55, Feb 20), NCI SPORE (5/17/18, 7/2018), NCI P01 (6/2018), CII (10/18/18), Reviewer for ORIEN New Oncologic Visionary Award (NOVA) and Austrian Science Fund (FWF) 2019: NIH P01 (2/6/2019), U54 (6/19/2019)

COMMITTEE: 2011-present: T32 Training Program in Transplantation Executive Committee member 2011-present: James Graham Brown Cancer Center Executive Committee member

Scientific Advisory Board: 2006- present: Scientific Advisory Board member, Biothera Inc., Eagen, MN

AWARDS FROM TRAINEES:

Stephanie Wagner, MD: First Place in Research!Research (Clinical Fellow) Best fellow presenter at the Southern Society of Clinical Investigation (New Orleans), 2007 Michael Driscoll, MD: Associates Research Poster prize at ACP (American College of Physicians) meeting in San Diego, 2007 Chuanlin Ding, Ph.D: Second place, James Graham Brown Cancer Center Annual Research Retreat, 2008 Dong Xiang, M.D: First Place in Research!Research (Clinical Fellow), 2009 First place, James Graham Brown Cancer Center Annual Research Retreat, 2009 Merit Award, 2011 Breast Cancer Symposium, San Francisco, CA Yunfeng Ma, Ph.D. First place, James Graham Brown Cancer Center Annual Research Retreat, 2011 Chris Fleming, M.D./Ph.D. candidate First place, Basic Science Doctoral Graduate Student Research Prize, Research!Louisville, 2013 First place, JG Brown Cancer Center Annual Research Retreat, 2013 First place, Midwest Regional American Physician Scientists Association Meeting

Yan CV, 2-15-2020

4

Sabrin Albeituni, Ph.D. Candidate Michael Tanner Memorial Award for Graduate Student Research!Louisville, 2013 Sabrin Albeituni, Ph.D. Candidate First place, JG Brown Cancer Center Annual Research Retreat, 2014 Paul Dascani, Ph.D Candidate 2018 AAI meeting Oral Presentation Anne Geller, MD/Ph.D. Candidate Third Place, Basic Science Doctoral Graduate Student Research Prize, Research!Louisville 2018 Samantha Morrissey, MD/PhD Candidate Travel Award, Keystone Meeting 2019

MD/Ph.D. Students: Daniel Allendorf (2006), Lacey Gunn (2011) Ph.D students: Sabrin Albetuni (2015), Chris Fleming (2016), Paul Dascani (2018) Current MD/Ph.D Students: Samantha Morrissey, Anne Geller Current PhD student: Rejeena Shrestha EDUCATIONAL ACTIVITIES

1997 – 1991: Course teaching: Basic Immunology and Tumor Immunobiology medical school students, Jiangsu University School of Medicine Role: Course Director. 30 courses, 200 students each year 2003: Cellular and Molecular Immunology for Graduate Students, Department of Microbiology and Immunology, University of Louisville Role: Lecturer. 4 courses, 12 students 2004: Cellular and Molecular Immunology for Medical School Students and Graduate Students, Department of Microbiology and Immunology, University of Louisville Role: Lecturer. 4 courses, 12 students 2005: Medical Microbiology and Immunology for medical school students, Department of Microbiology and Immunology, University of Louisville Role: Lecturer. 3 courses, 100 students Spring, 2006: Chinese Academy of Sciences. BIO2000 Role: Lecturer. 2 courses, 150 students Spring, 2006: Beijing University, China. BIO2000

Yan CV, 2-15-2020

5

Role: Lecturer. 2 courses, 150 students Fall, 2006: Medical Microbiology and Immunology, University of Louisville Role: Lecturer. 3 courses, 100 students Spring, 2007: Advance Immunology, Department of Microbiology and Immunology, University of Louisville Role: Lecturer. 4 courses, 12 students August 21, 2007: Medical Microbiology and Immunology, University of Louisville Role: Lecturer. 3 courses, 120 students Fall, 2007: Advance Immunology, Department of Microbiology and Immunology, University of Louisville Role: Lecturer. 3 courses, 10 students Spring, 2008: Advance Immunology, Department of Microbiology and Immunology, University of Louisville Role: Course Director and Lecturer. 1 course, 8 students September 4, 2008: Medical Microbiology and Immunology, University of Louisville Role: Lecturer. 3 courses, 100 students Spring, 2009: Advance Immunology, University of Louisville B Cells and Autoimmunity Role: Lecturer. 3 courses, 11 students September 22, 2009: Medical Microbiology and Immunology, University of Louisville Role: Lecturer. 3 courses, 120 students Fall, 2009: Advance Immunology, Department of Microbiology and Immunology, University of Louisville Role: Lecturer. 3 courses, 11 students Spring, 2010: Advance Immunology, University of Louisville B Cells and Autoimmunity Role: Lecturer. 3 courses, 10 students September, 2010: Medical Microbiology and Immunology, University of Louisville Role: Lecturer. 3 courses, 140 students

Yan CV, 2-15-2020

6

Fall, 2010: Advance Immunology, Department of Microbiology and Immunology, University of Louisville Role: Lecturer. 3 courses, 7 students Spring, 2011: Advance Immunology, University of Louisville B Cells and Autoimmunity Role: Lecturer. 3 courses, 8 students September, 2011: Medical Microbiology and Immunology, University of Louisville Role: Lecturer. 2 courses, 140 students September, 2012: Medical Microbiology and Immunology, University of Louisville Role: Lecturer. 1 course, 140 students November, 2013: Advance Immunology, University of Louisville Role: Lecturer. 1 course, 2 students. November, 2014: Advance Immunology, University of Louisville Role: Lecturer. 1 course, 4 students. November, 2015: Advance Immunology, University of Louisville Role: Lecturer. 1 course, 7 students March 7, 2016. Tumor Immunology. Course of Tumor Biology, University of Louisville November 2, 2016: Advance Immunology, University of Louisville March 7, 2017. Tumor Immunology. Course of Tumor Biology, University of Louisville November 1, 2017. Tumor Microenvironment. Advanced Immunology, University of Louisville Feb 27, 2018. Tumor Immunology, Course of Tumor Biology, University of Louisville Nov 31, 2018. Tumor Microenvironment. Advanced Immunology, University of Louisville

GRANTS AND CONTRACTS: Active funding:

Yan CV, 2-15-2020

7

PI: J. Yan (NIH P01CA163223-01A1, Co-PI and PI on Project#2) 03/01/2013 to 2/28/2020 Overall Title: Systems Biochemistry in Lung Cancer: Toward A Mechanistic Understanding of NSCLC Project#2: Determining Tumor Metabolism and Biochemical Mechanisms of b-Glucan Action in Mice The major goal of this proposal is to investigate how b-glucan treatment influences the metabolic profiles of tumor-infiltrating immune cells and subsequent tumor cell metabolism using lung carcinoma models.

PI: J. Yan (NIHR01CA213990) 02/01/2017 to 01/30/2022 Title: Transcriptional Regulation of Immunosuppressive Macrophages by c-Maf in Cancer The major goal of this proposal is to determine the cellular and molecular mechanisms by which transcription factor c-Maf regulates immunosuppressive macrophages in cancer. PI: J. Yan (NIH R01AI128818) 04/01/2017 to 03/30/2022 Title: Regulation of GDT cells by microbial pathogens/commensals in health and psoriasis The major goal of this proposal is to determine how microbial pathogens and/or skin commensals regulate innate GDT cells thus leading to skin inflammation. PI: J. Yan (NIH R21AI124081) 03/01/2016 to 03/01/2019 Title: Regulation of GC B Cells by Transcription Factor STAT3 The major goal of this proposal is to examine the underlying mechanisms by which STAT3 regulates GC formation and maintenance. PI: J. Yan (Kentucky Lung Cancer Research Program) 05/01/2015 to 4/30/2019 Title: Transcription Factor c-Maf in Lung Cancer-associated Macrophages The major goal of this proposal is to understand how transcription factor c-Maf regulates tumor-associated macrophages in lung cancer using animals and human patients. Co-PI: J. Yan (Kentucky Lung Cancer Research Program, PI: Haixun Guo) 06/30/2016 to 5/30/2019 Title: In vivo Investigation of Particulate beta-glucan on Lung Cancer Mouse Model The major goal of this proposal is to determine in vivo beta-glucan distribution in lung cancer models.

Yan CV, 2-15-2020

8

PI: J. Yan (NIH COBRE Pilot Project) 07/01/2016 to 6/30/2019 Title: Developing c-Maf Small Molecule Inhibitor for Cancer Immunotherapy The major goal of this proposal is to develop small molecule inhibitor of transcriptional factor c-Maf for cancer treatment. PI: J. Yan (National Psoriasis Foundation) 08/1/2017 to 7/30/2019 Title: Regulation of Innate GDT Cells in Skin Inflammation Co-I: J. Yan (NIH R01 CA193220-0A1, PI: Levi Beverly) 08/07/2015 to 07/31/2020 Title: Ubiqulin1 Regulates EMT and Metastasis of Human Lung Adenocarcinoma The major goal of this proposal is to understand how alterations in UBQLN1 signaling contributes to metastatic progression.

Co-I: J. Yan (NIH 1R44CA221487-01, PIs: Spencer W., Gupta R 09/26/2017 to 8/31/2019 Title: Exsomal Drug Delivery Co-I: J. Yan (Jewish Heritage Fund for Excellence), PI: Haixun Gup 02/01/2018 to 01/31/2020 Title: Developing Non-invasive Biomarkers for Personalized Immunotherapy of Lung Cancer

COMPLETED:

PI: J. Yan (NIH R21AI124235) 09/01/2015 to 08/30/2018 Title: Role of STAT3 Signaling in GC B Cell Regulation The major goal of this proposal is to understand the cellular and molecular mechanisms by which transcription factor STAT3 regulates GC B cell responses. PI: J. Yan 08/01/09 to 7/31/2015 NCI/NIH R01CA150947 20% effort DC: $1,000,000 Title: Mechanisms of Immune Modulation Mediated by Yeast-derived Particulate Beta-Glucan The major goal of this proposal is to understand the cellular and molecular mechanism of action of yeast-derived particulate b-glucans in cancer biology and therapy. PI: J. Yan 05/01/2012 to 06/30/2015 National Psoriasis Foundation $200,000 Title: Regulation of Psoriasis Pathogenesis by IL-1b Signaling Pathway

Yan CV, 2-15-2020

9

The major goal of this proposal is to understand how IL-1b signaling pathway regulates dermal gd T cell activation and IL-17 production. PI: J. Yan RSG-09-190-01-LIB 07/01/09 to 6/30/14 American Cancer Society 15% effort $720,000 Title: Targeting of Antigen to B Cells as a Novel Vaccine for Cancer Immunotherapy The major goal of this proposal is to develop a CD19 miniantibody fusion protein with tumor associate antigen Her-2/neu for breast cancer therapy. PI: J. Yan 02/23/2002 to 07/30/2012 NCI/NIH R01CA86412 20% effort, Direct Cost: $200,000/year Title: Ligation of CR3 by Glucan and iC3b Links Innate and Adaptive Anti-tumor Immunity The major goal of this application is to understand how leukocyte CR3 is triggered for cytotoxicity by iC3b opsonized tumor cells in combination with yeast b(1,3)-D-glucan. The knowledge gained from these studies will lead to a novel form of tumor immunotherapy that stimulates phagocytes and NK cells to kill iC3b-opsonized tumors. PI: J. Yan 12/01/2010 to 05/30/2014 Kentucky Lung Cancer Research Program $150,000 Title: Combined Orally Administered Yeast-derived b-Glucan with 1650G Tumor Vaccine in the Treatment of NSCLC The major goal of this proposal is to determine the adjuvant effect of b-glucan on lung cancer vaccine in mice and patients. PI: J. Yan 08/01/2010 to 7/31/2013 Alliance for Lupus Research $350,000 Title: Regulation of Autoreactive B Cells by Integrin ITGAM/CD11b The major goal of this proposal is to investigate the role of integrin CD11b in the regulation of autoreactive B cell activation and autoantibody production. PI: J. Yan 1/1/2011 to 5/30/2012 Mead Johnson Contracted Study $42,000 Title: Establishing non-clinical efficacy for the biological activity of bovine lactoferrin in infant formula in stimulating immune responses Co-I: J. Yan (NIH R21 CA198249-01, PI: Kavitha Yaddanapudi) 07/01/2015 to 06/30/2018 Title: A Novel Vaccination Strategy for Lung Cancer The major goal of this proposal is to develop ES cell based vaccine for lung cancer treatment.

Yan CV, 2-15-2020

10

Co-I: J. Yan 3/01/2007 to 2/28/2012 RO1DK074720-01A1 (PI: M. Ratajczak) 5% effort Direct Cost: $1,000,000 Title: Novel Hematopoietic Effects of C3 Cleavage Fragments The major goal of this proposal is to understand the role of complement C3 and its cleavage fragments in hematopoiesis Co-I: J. Yan 07/01/2009-6/30/2012 1 R21 CA133668-01A2 (PI: LANE, ANDREW N) 5% effort Direct Cost: $250,000 Project Title: Stable isotopomer analysis of anabolic metabolic pathways in breast cancer

PI: J. Yan OGMB 081373 11/01/08 to 10/30/09 Kentucky Lung Cancer Research Program $50,000 Title: Lung Cancer Bio-immunotherapy using Particulate Beta-Glucan in combination with the Anti-VEGF Monoclonal Antibody Bevacizumab The major goal of this project is to determine the synergistic therapeutic effect of particulate b-glucan with bevacizumab in xenograft lung carcinoma models. PI: J. Yan University of Louisville Competitive Enhancement Grant 03/01/2007 to 02/29/2008 Direct Cost: $13,000 Title: Development of a Novel Immunotherapy for Breast Cancer Co-PI: J. Yan James Graham Brown Cancer Center Pilot Project 03/01/2007 to 02/29/2008 Direct Cost: $50,000 Title: A Pilot Study of Immunological Effect of Beta-Glucan and Cetuximab in Lung Cancer Co-PI: J. YAN 08/01/05 to 07/31/06 James Graham Brown Cancer Center Pilot Grant Title: Phase II study of Rituximab plus beta-Glucan in patients with NHL, CLL, and SLL PI (sub-contractor): J. Yan 9/01/2006 to 8/31/2007 5% effort, Direct Cost: $100,000 NIH SBIR 1R43 AI071661-01 Title: Oral beta-glucan treats hematopoietic injury resulting from acute radiation exposure

Yan CV, 2-15-2020

11

The major goal of this application is to evaluate the efficacy of particulate b-glucan in promoting multi-lineage hematopoietic regeneration and enhancing survival when orally administered after whole body radiation exposure. PI: J. Yan 03/1/04 to 02/28/09 10% effort, Direct Cost: $300,000 Kentucky Lung Cancer Research Program Title: Development of a Novel Immunotherapy for Lung Carcinoma The major goal of this proposal is to develop a novel strategy by targeting tumor antigens to B cells for breaking immune tolerance to tumor cells. PI: J. Yan 09/1/03 to 08/30/07 10% effort, Direct Cost: $375,000 American College of Rheumatology Investigator Award Title: The Induction of T cell Tolerance or Autoimmunity by Autoreactive B cells The major goal of this project is to delineate how autoreactive B cells regulate the autoreactive T cell tolerance or activation using murine lupus model. PI: J. Yan 07/1/02 to 06/30/06 S.L.E Foundation Total direct cost: $150,000 Title: Lymphocyte Activation and Tolerance in Autoantibody Transgenic Mice The major goal of this proposal is to examine the molecular processing of U1/Sm snRNP autoantigen in immunoglobulin transgenic animals on normal and autoimmune-prone background.

MENTORED AWARD: Dr. Chuanlin Ding 07/01/07 to 06/30/2010 Arthritis Foundation Postdoctoral Fellowship Total: $150,000 Title: Regulation of Autoreactive B Cells by Plasmacytoid Dendritic Cells

PATENTS:

US UTILITY PATENT APPLICATION: Anti-CD19 Composition and Methods for Treating Cancer (14/251,263) PROVISIONAL DISCLOSURE: Glucan Compositions and Methods of Enhancing CR3-dependent Neutrophil-mediated Cytotoxicity (US60/814,148) PROVISIONAL DISCLOSURE: Particulate b-glucan Compositions for Regulating Dendritic Cells (US60/841,795) PROVISIONAL DISCLOSURE: Membrane Complement Regulatory Protein (mCRPs) Antagonists and Their Uses (US60/841,849)

Yan CV, 2-15-2020

12

PROVISIONAL DISCLOSURE: Combined b-Glucan with Avastin for Tumor Immunotherapy (US60/913,679)

EDITORIAL SERVICES (Peer Reviewer of Manuscripts)

Cancer Research Clinical Cancer Research Cancer Immunology Research Blood Leukemia Stem Cells FASEB Journal Nature Communications Nature Immunology Journal of Immunology Journal of Experimental Medicine European Journal of Immunology Journal of Leukocyte Biology Clinical Immunology Journal of Biological Chemistry Cellular Immunology Applied Microbiology and Biotechnology Vaccine Experimental Hematology Cell Reports Cancer Letters Cancer Science Journal of Immunology Cancer Immunology, Immunotherapy Proceedings of the National Academy of Sciences, U.S.A OncoTarget OncoImmunology PLosOne Journal of Translational Medicine Journal of Infectious Diseases Human Immunology Journal of Lipid Research Journal of Innate Immunity Journal of Investigative Dermatology Journal of Pathology British Journal of Dermatology

Editorial Boards:

International Journal of Immunology and Immunotherapy

Yan CV, 2-15-2020

13

World Journal of Stem Cells ABSTRATS AND PRESENTATATIONS: Oral/Invited Presentations: National/International Meetings

1. Yan, J., Ma, B.L. 1996. Costimulatory molecule CD80 (B7-1) expressed on human tumor cell lines. Abstract book in The Advanced Course and Symposium in Immunology. pp.178, Oct. 1996, Beijing (oral presentation)

2. Yan, J., Ma, B.L., Liu, G.Z. 1996. Studies on the relationship between T cell activated signals and cytokines production. Abstract book in The Advanced Course and Symposium in Immunology. pp199, Oct. 1996, Beijing (oral presentation)

3. Yan, J., and Mamula, M. J. T and B cell tolerance and autoimmunity in anti-snRNP transgenic mice. International Conference on Immunology Specialized Forums on Antigen, Antigen-presenting cells and T cells. Shanghai, China. 1999. (Oral and poster presentation).

4. Yan, J., Shlomchik, MJ., and Mamula, MJ. B cells are necessary and sufficient to prime autoreactive T cells in vivo. American Association of Immunologists Annual meeting, Denver, CO. 2003

5. Ross GD., Allendorf, DJ., Baran, JT., Yan, J., Haribabu, B., and Lambris JD. Tumor regression mediated by glucan against iC3b-opsonized tumors requires CR3+ neutrophils recruited via C5a and leukotriene B4. American Association of Immunologists Annual meeting. Denver, CO. 2003 (oral and poster presentation).

6. Ross GD., Allendorf, DJ., Baran, JT., Yan, J., Haribabu, B., and Lambris JD. Tumor regression mediated by glucan against iC3b-opsonized tumors requires CR3+ neutrophils recruited via C5a and leukotriene B4. American Association of Immunologists Annual meeting. Denver, CO. 2003 (oral and poster presentation).

7. Yan, J., Ding, CL., and Mamula, MJ. Breaking anti-tumor T cell tolerance by targeting tumor antigen to B lymphocytes. American Association of Immunologists Annual meeting. Washington DC. 2004 (Oral and poster presentation).

8. Li Wang, C., Ding, H., Al-Gwahi, J., Marroquin, J., Yan. Toll-like Receptor Agonists Stimulate Autoreactive B Cells. 2005. Arthritis Foundation Research Conference, Atlanta, GA (Oral presentation).

9. Chuanlin Ding, L., Wang, H., Al-Gwahi, J., Marroquin1, R., Hansen, J., Yan. Targeting Antigen to B Cells Through CD19 Overcomes Immune Tolerance to Tumor Antigen Mucin 1 in MUC1 Transgenic Mice. American Association of Immunologists Annual meeting. San Diego, CA. 2005 (Oral and poster presentation).

10. Bing Li, Daniel Allendorf, Richard Hansen, Jose Marroquin, Daniel Cramer, Claire Harris, Jun Yan. Importance of Decay Accelerating Factor (CD55) in Tumor Avoidance of Immune Destruction. American Association of Immunologists Annual meeting. Miami, FL. 2007 (oral presentation).

11. Jun Yan. Combined yeast b-glucan and anti-tumor mAb therapy requires C5a-mediated neutrophil chemotaxis via regulation of decay accelerating factor (CD55). 4th Workshop on Complement Associated Diseases, Animal Models and

Yan CV, 2-15-2020

14

Therapeutics. 2007. Greece (symposium presentation, 6/12/07) 12. Jun Yan. Plasmacytoid dendritic cells provide helper signal for autoreactive B

cell activation. International Immunology Conference. 2007. Shanghai (symposium presentation, 7/14/07)

13. Jun Yan. The Role of B Lymphocytes in Autoimmunity and Tumor. Nankai University, Tianjin, China (7/18/2007)

14. Jun Yan. Nutritional Priming of Innate Immunity. Royal Society of Medicine, London, United Kingdom. 2007

15. Jun Yan. Glucan-mediated Innate Immune Responses. Mead Johnson Nutritional Company, Evansville, IN. 2008

16. Jun Yan. Glucan-mediated Tumor Immunotherapy. Wuhan University, Wuhan, China. 2009

17. Jun Yan. Role of B Cells in Autoimmunity and Cancer. Suzhou University, Suzhou, China. 2009

18. Jun Yan. Combined b-glucan with Anti-tumor mAbs for Cancer Immunotherapy. Southern Illinois University School of Medicine. 2009.

19. Jun Yan. Effect of Yeast-derived β-Glucan in conjunction with Bevacizumab for the Treatment of Human Lung Adenocarcinoma in Subcutaneous and Orthotopic Xenograft Models. BIT Life Sciences' 7th Annual Congress of International Drug Discovery Sciences & Technology-2009 Shanghai. China

20. Jun Yan. b-Glucan-mediated Tumor Immunotherapy. University of Kentucky, Lexington. April, 2010.

21. Jun Yan. Complement Regulatory Protein in Cancer Therapy. Cell-Based Assays. San Francisco, CA. Oct 4-5. 2010

22. Jun Yan. Pivotal Role of gd T Cells in Psoriasis Pathogenesis. Shanghai Jiaotong University School of Medicine, Shanghai, China. Nov 8. 2010

23. Jun Yan. B Cell Autoimmunity in Lupus Pathogenesis. Suzhou University School of Medicine, Suzhou, China. March 3, 2011.

24. Jun Yan. b-Glucan-mediated Tumor Immunotherapy. National Taiwan University, Taiwan, China. May 18, 2011

25. Jun Yan. b-Glucan-mediated Hematopoietic Progenitor/Stem Cell Mobilization. The First Baltic Sea Stem Cell Meeting, Szczecin, Poland. May 28. 2011

26. Jun Yan. Pivotal Role of IL-17-producing gd T Cells in Skin Inflammation. Sino-US Immunology Conference, Changsha, China. August 4, 2011.

27. Jun Yan. Decorating Tumor Cells with Pathogen Components:b-Glucan-mediated Tumor Immunotherapy. Research!Louisville, Oct 10, 2011

28. Jun Yan. b-Glucan-mediated Tumor Immunotherapy. MD Anderson Cancer Center, Oct 18, 2011

29. Jun Yan. Tumor Immunotherapy. Shanghai Ruijin Hospital. Nov 7, 2011 30. Jun Yan. Role of dermal gd T cells in skin inflammation. Suchoow University

School of Medicine. Nov 14, 2011 31. Jun Yan. b-Glucan-mediated Tumor Immunotherapy: Recognizing Tumor Cells

as Pathogens by Immune Cells. Northwest University, Dec 12, 2011 32. Jun Yan. b-Glucan-mediated Immunotherapy in Cancer. University of Missouri

Yan CV, 2-15-2020

15

Cancer Center. March 20, 2012 33. Jun Yan. Negative Regulation of Autoreactive B Cell Activation by Integrin

CD11b Molecule. Alliance for Lupus Research Meeting. New York, May 11, 2012 34. Jun Yan. Translational Research Prospective. Tsinghua University, Beijing,

China. May 29, 2012 35. Jun Yan. Role of IL-1b Signaling Pathway in the Regulation of Dermal gd T

Cells. 9th International Conference on Innate Immunity. Rhodes, Greece. June 25, 2012

36. Jun Yan. Pivotal Role of Dermal gd T Cells in the Pathogenesis of Psoriasis. The Third International Conference on Regulatory T Cells and Th Subsets and Clinical Application in Human Diseases. Shanghai, China. Oct 13. 2012

37. Jun Yan. b-Glucan-mediated Tumor Immunotherapy. Saint Louis University. Dec 18, 2012.

38. Jun Yan. Dermal gdT Cells- A New Player in Psoriasis Pathogenesis. Boehringer Ingelheim. Danbury, CT. Feb 27. 2013.

39. Jun Yan. b-Glucan, A Potent Adjuvant to Engage both Innate and Adaptive Immunity. Vaccine And Gene Therapy Institute of Florida Corp. April 10, 2013.

40. Jun Yan. b-Glucan-mediated Tumor Immunotherapy-Engaging Innate Immune Cells. Columbus, Ohio State University. April 23, 2013.

41. Jun Yan. b-Glucan-mediated Tumor Immunotherapy. Zhejiang University. Oct 24, 2014

42. Jun Yan. Role of Innate Gammadelta T Cells in Skin Inflammation. The second International Conference on Health and Immunity. Guangzhou, Oct 29, 2014

43. Jun Yan. b-Glucan-mediated Tumor Immunotherapy. National Taiwan University. April 10, 2015

44. Jun Yan. Regulation of Autoreactive B Cell Activation by Integrin CD11b. Zhejiang Traditional Chinese Medical University. Oct. 10, 2015

45. Jun Yan. Modulation of Immunosuppressive Myeloid Cells for Effective Tumor Immunotherapy. GP Herzig Symposium. Louisville. 3/31/2016

46. Jun Yan. A Novel Subset of Innate IL-17-producing dermal gammadelta T cells in psoriasis pathogenesis. Society of Investigative Dermatology. Arizona. May 10, 2016.

47. Jun Yan. b-Glucan-mediated Tumor Immunotherapy: From Bench to Bedside. NCI/OCCAM: The State of the Science: Cancer Complementary and Alternative Medicine Therapeutics Research. Bethesda. May 25-26. 2016

48. Jun Yan. IL-17-producing gammadelta T cells in inflammation and cancer. Henry Ford Health System. November 7. 2016

49. Jun Yan. The Role of IL-1 Signaling in Psoriasis. UCSF. May 8. 2017 50. Jun Yan. IL-17-producing gammadelta T cells in cancer. Shanghai Jiaotong

University No. 9 Hospital. May 27. 2017 51. Jun Yan. The Role of Gammadelta T Cells in Inflammation and Cancer. Shanghai

Children’s Medical Center. July 30. 2017 52. Jun Yan. The Role of Gammadelta T Cells in Inflammation and Cancer. Southeast

University School of Medicine. Nanjing China, Nov 17, 2017.

Yan CV, 2-15-2020

16

53. Jun Yan. Beta-glucan-mediated Tumor Immunotherapy: From Bench to the Bedside. 2017 9th International Symposium of Tumor Biological Diagnosis and Therapy. Nanjing China, Nov 18, 2017.

54. Jun Yan. The Role of Gammadelta T Cells in Inflammation and Cancer. Jiangsu University School of Medicine. Zhenjiang China, Nov 21, 2017.

55. Jun Yan. Modulation of Tumor Microenvironment for Effective Tumor Immunotherapy. The 6th Guangzhou International Symposium on Oncology. Guangzhou China, Dec 2, 2017.

56. Jun Yan. Beta-Glucan-mediated Tumor Immunotherapy. University of Kentucky. April 9. 2018

57. Jun Yan. Role of IL-17-producing GDT cells in inflammation and Cancer. The Methodist Research Institute. Houston. April 23. 2018

58. Jun Yan. Keynote Speaker. The Chinese Dermatology Association Annual Meeting. The Role of IL-1b-IL-1R Signaling Pathway in Skin Inflammation. Kunming, China. June 22. 2018

59. Jun Yan. Beta-glucan-mediated Tumor Immunotherapy: from Bench to the Bedside. Shanghai Cancer Institute. June 27. 2018

60. Jun Yan. Tumor Immunotherapy: Past, Present, and Future. Shanghai 9th Hospital. Shanghai Jiaotong University. June 28. 2018

61. Jun Yan. Co-Chair and Co-Organizer, Tumor Immunotherapy Symposium, Hangzhou, Zhejiang, China. June 29-30. 2018

62. Jun Yan. Invited Speaker. City of Hope. March 25. 2019 63. Jun Yan. Invited Speaker. Emory University. June 7. 2019 64. Jun Yan. Invited Speaker. Moffitt Cancer Center. Dec 18. 2019

Poster Presentations: National/International Meetings:

65. Yan, J., Vetvika, V., Ross, G.D. 1998. Requirement for natural anti-tumor

antibodies (NtAb) for b-glucan therapy of murine mammary carcinoma. FASEB J. 12:A278. (poster presentation)

66. Yan, J., and Mamula, MJ. T cell autoimmunity in autoantibody transgenic mice. Keystone meeting. 2001 (poster presentation).

67. Yan, J., and Mamula, MJ. The regulation of T cell autoimmunity and tolerance in B cell transgenic mice. Lupus Foundation Forum. 2002 (poster presentation).

68. Yan, J., Shlomchik, MJ., and Mamula, MJ. Targeting tumor antigen to B cells breaks anti-tumor T cell tolerance. New England Immunology Conference. 2002 (poster presentation).

69. Yan., Shlomchik, MJ., and Mamula, MJ. B cells are necessary and sufficient to prime autoreactive T cells in vivo. The FESEB Journal. 2003 (oral and poster presentation).

70. Ross GD., Allendorf, DJ., Baran, JT., Yan, J., Haribabu, B., and Lambris JD. Tumor regression mediated by glucan against iC3b-opsonized tumors requires CR3+ neutrophils recruited via C5a and leukotriene B4. The FASEB Journal. 2003 (oral and poster presentation).

71. Allendorf, DJ., Baran, JT., Hansen RD., Hong, F., Marroquin, J., Yan, J., Walsh,

Yan CV, 2-15-2020

17

D., and Ross, GD. Macrophages shuttle orally administrated glucan to potentiate the CR3-dependent tumoricidal effects of monoclonal antibodies in mouse tumor models. The FASEB Journal. 2003 (poster presentation).

72. Yan, J., Ding, CL., and Mamula, MJ. Breaking anti-tumor T cell tolerance by targeting tumor antigen to B lymphocytes. The FASEB Journal. 2004 (Oral and poster presentation).

73. Allendorf D.J. Hansen R.D., Yan J., Baran J.T., Ross G.D. Macrophage processing of large triple helix-folded beta glucan produces a smaller single-chain beta glucan that functions to prime neutrophil CR3 and mediate regression of Ab and iC3b-opsonized tumors. Molecular Immunology 2004. 41:203

74. Ross G.D., Yan J., Hansen R.D., Allendorf D.J., Brandley B. Beta glucans augment the function of anti-tumor monoclonal antibodies (mAbs) by providing a novel mechanism for killing tumors via circulating blood neutrophils. 2004. International Society for Biological Therapy of Cancer.

75. Chuanlin Ding, L., Wang, H., Al-Gwahi, J., Marroquin1, R., Hansen, J., Yan. Targeting Antigen to B Cells Through CD19 Overcomes Immune Tolerance to Tumor Antigen Mucin 1 in MUC1 Transgenic Mice. FASEB Journal. 2005 (Oral and poster presentation).

76. Li Wang, C., Ding, H., Al-Gwahi, J., Marroquin, J., Yan. Toll-like receptor agonists stimulate “tolerogenic” anti-snRNP B cells for activation. FASEB Journal. 2005 (Oral and poster presentation).

77. D. E. Cramer, D. J. Allendorf, M. Z. Ratajczak, R. D. Hansen, G. D. Ross, J. Yan. Beta-glucan Enhancement of Complement Mediated Hematopoietic Recovery after Bone Marrow Injury. FASEB Journal. 2005

78. D. J. Allendorf, R., Hansen, J., Marroquin, B., Li, G., Ross, and J., Yan. PGG-Betafectin, a soluble b(1,3: 1,6) glucan, is processed by macrophages into an active moiety capable of priming neutrophil CR3 (CD11b) for cytotoxicity against iC3b- and monoclonal antibody-opsonized tumors. 2005. AACR meeting Abstract book.

79. Li Wang, C., Ding, H., Al-Gwahi, J., Marroquin, J., Yan. Toll-like Receptor Agonists Stimulate Autoreactive B Cells. 2005. Arthritis Foundation Research Conference (Oral presentation).

80. J., Yan, Daniel Allendorf, Bing Li, Richard Hansen. Beta-Glucans augment the killing activity of anti-tumor monoclonal antibodies by providing a novel mechanism that primes neutrophil CR3 to kill antibody targeted tumor cells. 2005. Era of Hope Department of Defense Breast Cancer Research Program meeting.

81. Reca R., Kucia M., Baran J., Yan J., Ratajczak M. Defective engraftment of HSPC from C3aR-/- mice reveals an underappreciated role of C3a-C3aR axis in stem cell homing to bone marrow. 2005. American Society of Hematology meeting.

82. Chuanlin Ding, Li Wang, Jose Marroquin, Daoxin Wang, Jun Yan. Interaction between pDC and autoreactive B cells in murine lupus model. 2006 American Association of Immunogists.

83. Li B, Allendorf A, Hansen R, Marroquin J, Ding, CL, Cramer D, and Jun Yan. Yeast beta-glucan amplifiers phagocyte killing of iC3b-opsonized tumor cells via Complement receptor 3-Syk-PI3-Kinase pathway. 2006. American Association of

Yan CV, 2-15-2020

18

Immunogists. 84. Cramer D, Li B, Ratajczak M, Hansen R, and Jun Yan. Soluble beta-glucan

induces stem cell mobilization. 2006. American Association of Immunologists. 85. Yan J, Li B, Marroquin J. Yesast beta-glucan PGG was processed by macrophage

to release active moiety for priming neutrophils. 2006. American Association for Cancer Research.

86. Carolina Salvador, Bing Li, Richard Hansen, Daniel Cramer, Jun Yan. Cytotoxicity of Bevacizumab is enhanced by b-glucan in tumors expressing membrane-bound VEGF. 2007. American Society of Clinical Oncology.

87. Bing Li, Daniel Allendorf, Richard Hansen, Daniel Cramer, Jun Yan. C5a mediated neutrophil chemotaxis in combined yeast b-glucan and anti-tumor immunotherapy is potentiated by regulation of the DAF (CD55). 2007. American Association for Cancer Research. Los Angeles, CA.

88. Chuanling Ding, Li Wang, Hayma Al-Gwahi, Jose Marroquin, Richard Hansen, Jun Yan. T and B Cell Immune Responses to Tumor Antigen MUC1 are Induced by Targeting Antigen to B Lymphocytes. 2007. American Association of Immunologists. Miami, FL.

89. Bing Li, Daniel Allendorf, Richard Hansen, Jose Marroquin, Daniel Cramer, Claire Harris, Jun Yan. Importance of Decay Accelerating Factor (CD55) in Tumor Avoidance of Immune Destruction. 2007. American Association of Immunologists (oral presentation). Miami, FL.

90. Daniel Cramer, Stephanie Wagner, Bing Li, Jingjing Liu, Richard Hansen, Ryan Reca, Mariusz Ratajczak, Jun Yan. Beta-Glucan Induced Mobilization of Hematopoietic Stem Cells Requires Matrix Metalloproteinase-9. 2007. American Association of Immunologists. Miami, FL.

91. Chuanlin Ding, Li Wang, Yihua Cai, Thomas Tedder, Suzanne Ildstad, Jun Yan. Plasmacytoid dendritic cells provide helper signal for autoreactive B cell activation. International Immunology Conference. 2007. Shanghai (symposium and poster presentation, 7/14/07), China.

92. Hong Xu, Jun Yan, Yiming Huang, Paula M. Chilton, Michael K Tanner, Lala-Rukh Hussain and Suzanne T. Ildstad. CD154 blockade prevents allosensitization through inhibiting both T and B-cell activation and decreasing expression of IFN-g and IL-10 in T-cells. 49th American Society of Hematology meeting. December 8-11, 2007. Georgia World Congress Center, Atlanta, Georgia.

93. Hong Xu, Jun Yan, and Suzanne T. Ildstad. CD154:CD40 Co-stimulatory Blockade: A Specific Approach to Prevent Sensitization to Donor Alloantigens. 49th American Society of Hematology meeting. December 8-11, 2007. Georgia World Congress Center, Atlanta, Georgia.

94. Huang, Y., Kucia, M., Atay, S., Hussain, L.R., Xu, H., Yan, J., Ratajczak, M.Z., and Ildstad, S.T.: Bone marrow transplantation temporarily improves the function of pancreas in streptozotocin-induced diabetes XXII International Congress of The Transplantation Society, Sydney, Australia, August 10-14, 2008 (Oral Presentation).

95. Xu, H., Huang, Y., Hussain, L-R, Yan, J., and Ildstad, S.T.: Blockade of CD154:CD40 co-stimulatory molecule interactions prevents sensitization to

Yan CV, 2-15-2020

19

alloantigen. The American Transplant Congress, May 31-June 4, 2008, Toronto, Ontario, Canada (Poster Presentation).

96. Ding CL., Wang L., Marroquin J., and Yan J. Activation of Autoreactive B cells by Interaction with CpG-stimulated Plasmacytoid Dendritic Cells. AAI San Diego 2008

97. Yan J., Particular Glucans Modulates Tumor Microenvironment Toward Th1 Responses. 2008 World Congress of Cancer, Shanghai, China (Symposium Talk)

98. Hong Xu, Ziqiang Zhu, Lala-Rukh Hussain, Yiming Huang, Larry D. Bozulic, Jun Yan and Suzanne T. Ildstad. Immune-based non-myeloablative conditioning to establish mixed chimerism and donor-specific tolerance: Targeting adaptive T and B cell responses. 50th ASH Annual Meeting, San Francisco, CA. Dec 6-9, 2008

99. Ding CL and Jun Yan. Full Activation of Autoreactive B Cells Requires Helper Signals from Plasmacytoid Dendritic Cells. AAI meeting, Seattle. 2009

100. Ding CL, Cai, YH, and Jun Yan. Dominant epitope p21-40 of snRNP D protein recognized by both autoreactive T and B cells in lupus-prone MRL lpr/lpr mice. AAI meeting 2010. Baltimore.

101. Gunn, L., Cai, YH, Hu, XL., Ding, CL., Qi, CJ., Hansen, R., Jun Yan. Role of Complement Activation Component C5a on Tumor Progression AAI meeting 2010. Baltimore.

102. Ding CL and Jun Yan. Role of Intergrin CD11b Molecule in the Regulation of Autoreactive B Cells. AAI meeting 2011. San Francisco.

103. Cai YH and Jun Yan. Pivotal Role of Dermal gd T Cells in the Pathogenesis of Psoriasis. AAI meeting 2011. San Francisco.

104. Gunn L and Jun Yan. Tumor Microenvironment Modulated by Complement Component C5a. AAI meeting 2011. San Francisco.

PUBLICATIONS (Google Scholar H-index: 53 Citation: 12235) Articles published in Peer-Reviewed Journals:

1. Cai Y., Xue F., Qin H., Chen X., Liu N., Fleming C., Hu X., Zhang H., Chen F., Zheng J.,

and Yan J. Differential Roles of the mTOR-STAT3 Signaling in Dermal gdT Cell Effector Function in Skin Inflammation. Cell Reports. 2019. 27:3034-3048.

2. Geller A., and Yan J. The Role of Membrane Bound Complement Regulatory Proteins in Tumor Development and Cancer Immunotherapy. Frontier in Immunology. 2019. 10:1074

3. Geller A, Shrestha R, and Yan J. Yeast-derived Beta-Glucan in Cancer: Novel Uses of a Traditional Therapeutic. International Journal of Molecular Sciences. 20(15)

4. Cai Y., Xue F., Quan C., Qu M, Liu N., Zhang Y., Fleming C., Hu X., Zhang HG.,

Weichselbaum R., Fu YX., Tieri D., Rouchka EC., Zheng J., and Yan J. A Critical Role of the IL-1b-IL-1R Signaling Pathway in Skin Inflammation and Psoriasis Pathogenesis. Journal of Investigative Dermatology. 2019. 139:146-156. PMID: 30120937

Yan CV, 2-15-2020

20

5. Ding C, Sun X, Wu C, Hu X, Zhang HG, and Yan J. Tumor Microenvironment Modulates Immunological Outcomes of Myeloid Cells with mTOC1 Disruption. Journal of Immunology. 2019. 202: 1623-1634. PMID: 30665937.

6. Teng Y, Ren Y, Sayed M, Hu X, Lei C, Kumar A, Hutchins E, Mu J, Deng Z, Luo C, Sundaram K, Sriwastva MK, Zhang L, Heish M, Reiman R, Haribabu B, Yan J, Jala VR, Miller DM, Van Keuren-Jensen K, Merchant ML, McClain CJ, Park JW, Egilmez NK, Zhang HG. Plant-derived Exosomal MicroRNAs Shape the Gut Microbiota. Cell Host and Microbe. 2018. 24: 637-652. PMID: 30449315

7. Dascani P, Ding C, Kong X, Tieri D, Hu X, Zhang HG, Kitamura D, Bolli R, Rouchka E, and Yan J. Transcription Factor STAT3 Serves as a Negative Regulator Controlling IgE Class Switching in Mice. ImmunoHorizons. 2018. 2: 349-362. PMID: 31026806

8. Wang QL, Zhuang X, Sriwastva MK, Mu J, Teng Y, Deng Z, Zhang L, Sundaram K, Kumar A, Miller D, Yan J, Zhang HG. Blood Exosomes Regulate the Tissue Distribution of Grapefruit-derived Nanovector via CD36 and IGRF1 Pathways. Theranostics. 2018. 8:4912-24. PMID: 30120937.

9. Li X, Rouchka EC., Brock GN., Yan J., O’Toole TE., Tieri DA., Cooper NGF. A Combined Approach with Gene-wise Normalization Improves the Analysis of RNA-seq Data in Human Breast Cancer Subtypes. PlosOne. 2018 PMID:30089167

10. Sun X, Cai Y, Fleming, C, Tong Z, Wang, ZL, Ding C, Zhang HG, Suo J, Yan J. Innate γδT17 Cells Play A Critical Role in DSS-induced Colitis via Recruitment of Gr-1+CD11b+ Myeloid Suppressor Cells. Oncoimmunology, 2017. e1313369

11. Fleming C*, Cai Y*, Sun X, Venkatakrishna J, Xue F, Morrissey S, Wei YL, Chien YH, Zhang HG, Haribabu B., Huang J., Yan J. Microbiota Activated CD103+ DCs Stemming from Microbiota Adaption Specifically Drive γδT17 Proliferation and Activation. Microbiome, 2017. 5(1):46 (* co-first author)

12. Fleming C, Morrissey S, Cai Y, Yan J. GDT Cells: Unexpected Regulators for Cancer

Development and Progression. Trends in Cancer, 2017. 3(8):561-570

13. Hu G, Wu P, Cheng P, Zhang Z, Wang Z, Yu X, Shao X, WU D, Ye J, Zhang T, Wang X, Qiu F, Yan, J* and Huang J*. Tumor-infiltrating CD39+GDTregs are novel immunosuppressive T cells in human colorectal cancer. Oncoimmunology. 6(2):e1277305. doi: 10.1080/2162402X.2016.1277305. PMID: 2834489. 2017 (*co-corresponding authors)

14. Yan J. Identifying biomarkers in human psoriasis: revealed by systems metabolomics

approach. British Journal of Dermatology. Editorial. 176(3):555-557. PMID: 28300304. 2017.

Yan CV, 2-15-2020

21

15. Teng Y, Ren Y, Hu X, Mu J, Samykutty A, Zhuang X, Deng Z, Kumar A, Zhang L, Merchant ML, Yan J, Miller DM, Zhang HG. MVP-mediated exosomal sorting of miR-193a promotes colon cancer progression. Nature Communications. 8:14448. doi: 10.1038/ncomms14448. PMID: 28211508. 2017.

16. Deng Z, Rong Y, Teng Y, Mu J, Zhuang X, Tseng M, Samykutty A, Zhang L, Yan J,

Miller D, Suttles J, Zhang HG. Broccoli-derived nanoparticle inhibits mouse colitis by activating dendritic cell AMP-activated protein kinase. Molecular Therapy. Pii:s1525-0016(17)30064-3. PMID: 28274798. 2017

17. Lane AN, Tan J, Wang Y, Yan J, Higashi RM, Fan TW. Probing the metabolic of

breast cancer cells by multiple tracer stable isotope resolved metabolomics. Metabolic Engineering. doi: 10.1016/j.ymben. 2017.

18. Bujko K, Rzeszotek S, Hoehig K, Yan J, Vater A, Ratajczak M. Signaling of the

Complement Cleavage Product Anaphylatoxin C5a Through C5aR (CD88) Contributes to Pharmacological Hematopoietic Stem Cell Mobilization. Stem Cell Rev. doi: 10.1007/s12015-017-9769-6

19. Albeituni S, Ding C, Liu M, Hu X, Luo F, Klocker G, Bousamra M, Zhang HG, Yan

J. Yeast-derived Particulate β-Glucan Treatment Subverts the Suppression of Myeloid-derived Suppressor Cells by Inducing Polymorphonuclear MDSC Apoptosis and Monocytic MDSC Differentiation into APC in Cancer. Journal of Immunology. 196(5):2167-80. PMCID: 4761495. 2016.

20. Ding C, Chen X, Dascani P, Bolli R, Zhang HG, Mcleish K, and Yan J. STAT3 Signaling in B Cells Is Critical for the Germinal Center Maintenance and Contributes to the Pathogenesis of Murine Models of Lupus. Journal of Immunology. 196(11):4477-86. PMCID: 4875824. 2016.

21. Krem MM and Yan J. To B(ortezomib) or Not to Be: the Stroma’s the Thing. Journal

of Pathology. 40(2):123-5. 2016.

22. Ye H, Wang Y, Jenson, AB, and Yan J. Idendification of Inflammatory Factor TNF-a Inhibitor from Medicinal Herbs. Exp Mol Path. 100:307-11. 2016.

23. Sun X, Suo J, and Yan J. Immunotherapy in Human Colorectal Cancer: Challenges

and Prospective. World Journal of Gastroenterology. 22:6363-6372. 2016.

24. Zhuang X, Tseng Y, Samykutty A, Mu J, Deng Z, Zhang L, Cao P, Rong Y, Yan J, Miller D, Zhang HG. Grapefruit-derived Nanovectors Delivering Therapeutic miR17 Through an Intranasal Route Inhibit Brain Tumor Progression. Molecular Therapy. 24:96-105. 2016.

Yan CV, 2-15-2020

22

25. Deng Z, Rong Y, Teng Y, Zhuang X, Samykutty A, Mu J, Zhang L, Cao P, Yan J, Miller D, Zhang HG. Exosomes miR-126a released from MDSC induced by DOX treatment promotes lung metastasis. Oncogene. Doi:10.1038/onc.2016.229. 2016.

26. Park J, Kim S, joh J, Remick, SC, Miller DM, Yan J, Kanaan Z, Chao JH, Krem MM,

Basu SK, Hagiwara S, Kenner L, Moriggl R, Bunting KD, Tse W. MLLT11/AF1q boosts oncogenic STAT3 activity through Src-PDGFR tyrosine kinase signaling. Oncotarget. Doi:10.18632/oncotarget.9759. 2016.

27. Zhang HG, Cao P, Teng Y, Hu X, Wang Q, Yeri AS, Zhuang X, Samykutty A, Mu J,

Deng ZB, Zhang L, Mobley JA, Yan J, Van Keuren-Jensen K, Miller D. Isolation, identification, and characterization of novel nanovesicles. Oncotarget. Doi:10.18632/oncotarget.9325. 2016.

28. Teng Y, Mu J, Hu X, Samykyttt A, Zhuang X, Deng Z, Ahang L, Cao P, Yan J,

Miller D, Zhang HG. Grapefruit-derived nanovectors deliver miR-18a for treatment of liver metastasis of colon cancer by induction of M1 macrophages. Oncotarget. 7:25683-97. 2016.

29. Liu M, Luo F, Ding C, Albeituni S, Hu X, Ma Y, Cai Y, McNally L, Sanders M, Jain

D, Kloecker G, Bousamara M, Zhang HG, Higashi R, Lane AN, Fan TWM, Yan J. Dectin-1 Activation by a Natural Product β-Glucan Converts Immunosuppressive Macrophages into an M1 Phenotype. Journal of Immunology. 195:5055-65. PMCID: 4637216. 2015.

30. Lane AW, Yan J, Fan TW. 13C Tracer Studies of Metabolism in Mouse Tumor

Exnografte. Bio Protoc. Pii:bio-protocol.org/e1650. 2015.

31. Wu D, Wu P, Wu X, Ye J, Wang Z, Zhao S, Ni C, Hu G, Xu J, Han Y, Zhang T, Qiu F, Yan J * and Huang J . Ex vivo expanded human circulating Vd1 gdT cells exhibit favorable therapeutic potential for colon cancer. Oncoimmunology. 4(3):e992749. (Corresponding authors). 2015.

32. Wang Q, Ren Y, Mu J, Egilmez NK, Zhuang X, Deng Z, Zhang L, Yan J, Miller D,

Zhang HG. Grapefruit-derived Nanovectors Use an Activated Leukocyte Trafficking Pathway to Deliver Therapeutic Agents to Inflammatory Tumor Sites. Cancer Research. 75(12):2520-9. 2015.

33. Deng Z, Mu J, Tseng M, Wattenberg B, Zhuang X, Egilmez NK, Wang Q, Zhang L,

Norris J, Guo H, Yan J, Haribabu B, Miller D, Zhang HG. Enterobacteria-secreted particles induce production of exosome-like S1P-containing particles by intestinal epithelium to drive Th17-mediated tumorigenesis. Nature Communications. 6:6956. 2015.

Yan CV, 2-15-2020

23

34. Sellers K, Fox MP, Bousamara M, Slone SP, Higashi R, Miller DM, Wang Y, Yan J, Yuneva MO, Deshpande R, Lane AN, Fan TW. Pyruvate Carboxylase is Critical for Non-small Cell Lung Cancer Proliferation. Journal of Clinical Investigation. 125(2): 687-98. 2015.

35. Hudson SV, Huang JS, Yin W, Albeituni S, Rush J, Khanal A, Yan J, Ceresa B, Frieboes HB, McNally LR. Targeted Non-invasive Imaging of EGFR-expressing Orthotopic Pancreatic Cancer using Multispectral Optoacoustic Tomography (MSOT). Cancer Research. 74(21):6271-9. 2014.

36. Wu P, Wu D, Ni C, Ye J, Chen W, Hu G, Wang Z, Wang C, Zhang Z, Xia W, Chen Z,

Wang K, Zhang T, Xu J, Han Y, Zhang T, Wu X, Wang J, Gong W, Zheng S, Qiu F, Yan J* and Huang J*. gdT17 Cells Promotes the Accumulation and Expansion of Myeloid-Derived Suppressor Cells in Human Colorectal Cancer. Immunity. 00147-2. doi: 10.1016/j.immuni (*Corresponding authors). 2014.

37. *Cai Y, Xue F, Fleming C, Yang J, Ding C, Ma Y, Liu M, Zhang HG, Zheng J, Xiong N, and Yan J. Differential Developmental Requirement for Dermal IL-17-producing Vg4 and Vg6 T Cells and Their Peripheral Regulation in Health and Skin Inflammation. Nature Communications. 5:3986. DOI: 10.1038/ncomms4986. 2014.

38. Yan J, Kloecker G, Fleming C, Hansen R, Hu X, Ding C, Cai Y, Dong X, Donninger

H, Eaton JW, Clark G. Human Polymorphonuclear Neutrophils Specifically Recognize Tumor Cells for Killing. OncoImmunology. e950163 DOI:10.4161/15384101.2014.950163. 2014.

39. Yan J, and Huang J. Innate gdT17 Cells Convert Cancer-elicited Inflammation into

Immunosuppression through Myeloid-derived Suppressor Cells. OncoImmunology. e953423 DOI:10.4161/21624011.2014.953423. 2014.

40. Jiang H, Wang P, Li X, Wang Q, Deng ZB, Zhuang X, Mu J, Zhang L, Wang B, Yan J, Miller D, Zhang HG. Restoration of miR17/20a in Solid Tumors Enhances the Natural Killer Cells Antitumor Activity by Targeting Mekk2. Cancer Immunology Research. May 6. PMID: 24801835. 2014.

41. Jiang H, Wang P, Wang Q, Mu J, Zhang L, Wang B, Yan J, Miller D, Zhang HG.

Quantitatively Controlling Expression of miR-17-92 Determines Colon Tumor Progression in A Mouse Tumor Model. American Journal of Pathology. 184:1355-68. 2014.

42. Wang S, Zhou H, Feng T, Wu R, Sun X, Guan N, Qu L, Gao Z, Yan J, Xu N, Zhao J,

Qi C. b-Glucan Attenuates Inflammatory Responses in Oxidized LDL-induced THP-1 Cells via the p38 MAPK Pathway. Nutrition, Metabolism & Cardiovascular Diseases. 24:248-55. 2014.

Yan CV, 2-15-2020

24

43. Mu J, Zhuang X, Wang Q, Jiang H, Deng ZB, Wang B, Zhang L, Kakar S, Yan J, Miller D, Zhang HG. Interspecies Communications between Plant and Mouse Gut Host Cells Through Edible Plant-derived Exosome-like Nanoparticles. Molecular Nutrition Food Research. Doi: 10.1002/mnfr.201300729. 2014.

44. Ma Y, Xiang D, Sun J, Ding C, Liu M, Hu X, Kloecker G, Zhang HG, and Yan J.

Targeting of Antigens to B Lymphocytes via CD19 As A Means for Tumor Vaccine Development. Journal of Immunology. 190(11):5588-99. 2013

45. *Ding C, Ma Y, Chen X, Liu M, Cai Y, Hu X, Xiang D, Nath S, Zhang HG, Ye H, Powell D, and Yan J. Integrin CD11b Negatively Regulates BCR Signaling to Maintain Autoreactive B Cell Tolerance. Nature Communications. 4:2813. doi: 10.1038/ncomms3813. 2013.

46. Albeituni S, Ding C, and Yan J. Hampering the Immune Suppressor: Therapeutic

Targeting of Myeloid-derived Suppressor Cells (MDSC) in Cancer. The Cancer Journal. 19(6):490-501. 2013.

47. Wang Q, Zhuang X, Mu J, Deng Z, Jiang H, Xiang X, Wang B, Yan J, Miller D,

Zhang HG. A Grapefruit-derived Nano Vector Enables Multi-model Strategies to Deliver Therapeutic Agents. Nature Communications. 4:1867. doi: 10.1038/ncomms2886. 2013

48. Wang B, Zhuang X, Deng ZB, Jiang H, Mu J, Wang Q, Xiang X, Guo H, Zhang L,

Dryden G, Yan J, Miller D, Zhang HG. 2013. Targeted Drug Delivery to Intestinal Macrophages by Bioactive Nanovesicles Released from Grapefruit. Molecular Therapy. Auguest 13. Doi: 10.1038/mo. PMID:23939022

49. Tian J, Ma J, Ma K, Guo H, Baidoo SE, Zhang Y, Yan J, Lu L, Xu H, Wang S. b-

Glucan Enhances Anti-tumor Immune Responses by Regulating Differentiation and Function of Monocytic Myeloid-derived Suppressor Cells. European Journal of Immunology. 43(5):1220-30. 2013.

50. Wu X, Chen X, Zhou Q, Li P, Yu B, Li J, Qu Y, Yan J, Yu Y, Yan M, Zhu Z, Liu B, Su L. Hepatocyte Growth Factor Activates Tumor Stromal Fibroblasts to Promote Tumorigenesis in Gastric Cancer. Cancer Letters. 335:128-35 PMID: 23402812. 2013.

51. Cai, Y.H., Fleming, C., and Yan, J.: Dermal gdT Cells- A New Player in the Psoriasis Pathogenesis. International Immunopharmacology. 16(3):388-91. 2013. PMID:23499509

52. Ju S, Mu J, Dokland T, Zhuang X, Wang Q, Jiang H, Xiang X, Deng ZB, Wang B,

Zhang L, Roth M, Welti R, Mobley J, Yan J, Miller D, Zhang HG. Grape Exosome-like Nanoparticles Induce Intestinal Stems Cells and Protect Mice from DSS-Induced Colitis. Molecular Therapy. 21(7):1345-57. 2013

Yan CV, 2-15-2020

25

53. Yu B, Chen X, Li J, Qu Y, Su L, Peng Y, Huang J, Yan J, Yu Y, Gu Q, Zhu Z, Liu B.

Stromal Fibroblasts in the Microenvironment of Gastric Carcinoma Promotes Tumor Metastasis via Upregulating TGALN Expression. BMC Cell Biology. 14:17. doi: 10.1186/1471-2121-14-17. 2013.

54. Deng ZB , Ju S, Zhuang X, Xiang X, Mu J, Hong J, Zhang L, Mobley J , McClain C,

Yan J, Miller DM, Kronenberg M, Zhang HG. Intestinal Mucus Exosome-like Nanoparticles Carry Prostaglandin E2 and Suppress Activation of Liver Natural Killer T Cells. Journal of Immunology. 190(7):3579-89. 2013.

55. Deng, ZB., Zhuang, X., Ju, S., Xiang, X., Mu, J., Wang, Q., Hong, J., Zhang, L.,

Kronenberg, M., Yan, J., Miller, D., and Zhang, HG. Intestinal Mucus-derived Nanoparticles Mediate Activation of Wnt/β-catenin Signaling Plays a Role in Induction of Liver NKT Cell Anergy. Hepatology. 57(3):1250-61. 2013. PMID:22991247

56. Albeituni, S., and Yan, J.: The Effects of b-Glucans on Dendritic Cells and Implications for Cancer Therapy. Anti-cancer Agents in Medicinal Chemistry. 13(5):689-98. 2013. PMID:23092290

57. Gunn, L., Ding, CL., Liu, M., Ma, YF., Qi, CJ., Cai, YH., Hu, XL., Aggarwal, D.,

Zhang, HG., and Yan J.: Opposing Roles for Complement Component C5a in Tumor Progression and the Tumor Microenvironment. Journal of Immunology. 189(6):2985-94. 2012.

58. Xiang, D., Sharma, V.R., Freter, C.E., and Yan, J.: Anti-tumor Monoclonal Antibodies in Conjunction with b-Glucans: a Novel Anti-Cancer Immunotherapy. Current Medicinal Chemistry. 19(25):4298-305. PMID:22834812. 2012.

59. Xu, H.,*, Yan, J., *, Huang, YM., Chilton, PM., Ding, CL., Schanie, CL., and Ildstad,

ST. TLR4/TRIF Pathway Controls Innate Immune Cell-mediated Rejection for Allogeneic Bone Marrow Cells. Cell Transplantation. In press (*co-first author) 2012. PMID:23146386

60. Xiang X, Deng Z, Zhuang X, Ju S, Mu J, Jiang H, Zhang L, Yan J, Miller D, Zhang

HG. Grhl2 Determines the Epithelial Phenotype of Breast Cancers and Promotes Tumor Progression. PLoS One. 7(12):e50781. 2012. PMID:23284647

61. Tian J, Ma J, Ma K, Ma B, Tang X, Baidoo SE, Tong J, Yan J, Lu L, Xu H, Wang S.

Up-Regulation of GITRL on Dendritic Cells by WGP Improves Anti-Tumor Immunity in Murine Lewis Lung Carcinoma. PLoS One. 7(10):e46936. 2012.

62. Yaddanapudi, K., Mitchell, RA., Putty, K., Willer, S., Sharma, RK., Yan, J.,

Yan CV, 2-15-2020

26

Bodduluri, H., Eaton, JW.: Vaccination with Embryonic Stem Cells Protects against Lung Cancer: Is a Broad-Spectrum Prophylactic Vaccine against Cancer Possible? PLos One. 7:e42289. 2012.

63. Cai, YH., Fleming, C., and Yan J.: New Insights of T Cells in the Pathogenesis of

Psoriasis. Cellular and Molecule Immunology. 9(4):302-9. 2012.

64. Xu H., Zhu Z., Huang Y., Bozulic LD., Hussain L., Yan J., Ildstad ST. Innate as well as Adaptive Immune Responses Are Tolerized in Chimeras Prepared with Non-Myeloablative Conditioning. Transplantation. 15;93(5):469-76. 2012.

65. Deng Z, Cheng Z, Xiang X, Yan J, Zhuang X, Liu C, Jiang H, Ju S, Zhang L, Grizzle

W, Mobley J, Roman J, Miller D, Zhang HG. Tumor Cell Cross Talk with Tumor-Associated Leukocytes Leads to Induction of Tumor Exosomal Fibronectin and Promotes Tumor Progression. American Journal of Pathology. 180(1):390-8. 2012.

66. Cai, YH., Shen, XY., Ding, CL., Qi, CJ., Li, KJ., Li, X., Jala, VR., Zhang, HG., Wang,

T., Zheng, J., and Yan J.: Pivotal Role of Dermal IL-17-producing gd T Cells in Skin Inflammation. Immunity. 35(4):596-610. 2011.

67. Qi, C., Cai, YH., Gunn, L., Ding, CL., Li, B., Kloecker, G., Qian, K., Vasilakos, J., Saijo, S., Iwakura, Y., Yannelli, JR., and Yan J.: Differential Pathways Regulating Innate and Adaptive Anti-tumor Immune Responses by Particulate and Soluble Yeast-derived b-Glucans. Blood. 117(25):6825-36. 2011.

68. Tian, J., Ma, J., Wang, S*., Yan, J*., Chen, J., Tong, J., Wu, C, Liu, Y., Ma, B., Mao, C., Jiao, Z., Shao, Q., Lu, L., Xu, H.: Increased expression of mGITRL on D2SC/1 cells by particulate b-glucan impairs the suppressive effect of CD4+CD25+ regulatory T cells and enhances the effector T cell proliferation. Cellular Immunology, 270:183-7. 2011. * co-corresponding author

69. Fan, TW., Lane, AN., Higashi, R., and Yan J.: Stable Isotope Resolved Metabolomics

of Lung Cancer in a SCID Mouse Model. Metabolomics. 1;7(2):257-269. 2011.

70. Kong M., and Yan, J.: Modeling and Testing Treated Tumor Growth Using Cubic Smoothing Splines. Biometrical Journal, 53(4):595-613. 2011.

71. Lane, AN., Fan, TW., Bousamra, M., Higashi, R., Yan, J., Miller, DM.: Clinical Applications of Stable Isotope-resolved Metabolomics (SIRM) in Non-Small Cell Lung Cancer. OMICS: A Journal of Integrative Biology, 15(3):173-82, 2011.

72. Li, B., Cai, YH., Qi, CJ., Hansen, R., Ding, CL., Mitchell, TC., and Yan J.: Orally Administrated Particular b-Glucan Modulates Tumor-capturing Dendritic Cells and Improves Anti-tumor T Cell Responses in Cancer. Clinical Cancer Research, 16(21):5153-64, 2010.

Yan CV, 2-15-2020

27

73. Huang YM, Kucia M, Hussain L, Wen Y, Xu H, Yan J, Ratajczak MZ, and Ildstad

ST.: Bone Marrow Transplantation Temporarily Improves Pancreatic Function in Streptozotocin-Induced Diabetes: Potential Involvement of Very Small Embryonic-Like Cells. Transplantation. 89(6):677-85, 2010.

74. Xu, H., Huang YM., Hussain L, Ding CL., Yan J., and Ildstad ST.: Sensitization to minor antigens is a significant barrier in bone marrow transplantation and is prevented by CD154:CD40 blockade. American Journal of Transplantation. 10(7):1569-79, 2010.

75. Goga L, Perez-Abadia G, Pushpakumar S, Cramer D, Yan J, Todnem N, Anderson G,

Soni C, Barker J, Maldonado C.: 2010. Cell Membrane Modification for Rapid Display of Bi-Functional Peptides: A Novel Approach to Reduce Complement Activation. The Open Cardiovascular Medicine Journal. 4:157-165. PMCID: 2948132

76. Ding C, Cai Y, Marroquin J, Ildstad ST, Yan J.: Plasmacytoid Dendritic Cells

Regulate Autoreactive B Cell Activation via Soluble Factors and in a Cell-to-Cell Contact Manner. Journal of Immunology. 183(11):7140-9, 2009.

77. Zhong WJ., Hansen R, Li B., Cai Y, Salvador C., Moore GD., Yan J.: Effect of Yeast-derived β-Glucan in conjunction with Bevacizumab for the Treatment of Human Lung Adenocarcinoma in Subcutaneous and Orthotopic Xenograft Models. Journal of Immunotherapy 32(7):703-12, 2009.

78. Ma YF, Chen HD, Wang QL, Luo FL, Yan J, and Zhang XL. IL-24 stimulates early

neutrophils to produce Th1 cytokines, subsequently activating CD8+ T cells for defense against Salmonella typhimurium infection. European Journal of Immunology Dec;39(12):3357-68, 2009.

79. Driscoll M, Hansen R, Ding C, Cramer DE, Yan, J.: Therapeutic Potential of Various β-Glucan Sources in Conjunction with Anti-Tumor Monoclonal Antibody in Cancer Therapy. Cancer Biology & Therapy, 3:8(3):216-223, 2009.

80. Liu J, Gunn L, Li B, Hansen R, Yan, J.: Combined Yeast-derived b-Glucan and Anti-

tumor Monoclonal Antibody for Cancer Immunotherapy. Experimental and Molecular Pathology. 86:208-214, 2009.

81. Liu J, Gunn L, Hansen R, Yan, J.: Yeast-derived b-Glucan in Combination with Anti-

tumor Monoclonal Antibody Therapy in Cancer. Current Patents on Anti-cancer Drug Discovery. 4:101-109, 2009.

Yan CV, 2-15-2020

28

82. Tan Y, Li Y, Xiao J, Shao S, Ding C, Arteel GE, Webster KA, Yan J, Yu H, Lu Cai L, and Li X. A Novel CXCR4 Antagonist Derived from Human SDF-1β Enhances Angiogenesis in Ischemic Mice. Cardiovascular Research, 82:513-521, 2009.

83. *Ding CL, Wang L, Marroquin J, Yan, J.: Targeting of Antigens to B Cells Augments

Antigen-specific T Cell Responses and Breaks Immune Tolerance to Tumor-associated Antigen MUC1. Blood 112(7):2817-25, 2008.

84. Yan J, Allendorf DJ, Li B, Yan R, Hansen R, Donev R.: The role of membrane

complement regulatory proteins in cancer immunotherapy. Adv Exp Med Biol. 632:159-74, 2008.

85. Xu, H., Huang, Y., Chilton, P.M., Hussain, L.R., Tanner, M.K., Yan, J., and Ildstad,

S.T.: Strategic nonmyeloablative conditioning: CD154:CD40 co-stimulatory blockade at primary BMT promotes engraftment for secondary BMT after engraftment failure. Journal of Immunology 181(9):6616-24, 2008.

86. Cramer, DE, Wagner, S, Li, B, Liu, J., Hansen, R., Reca, R., Wu, W., Zuba-Surma, E.,

Lamber, D., Ratajczak, MZ, Yan, J.: Mobilization of Hematopoietic Progenitor Cells by Yeast-derived b-Glucan Requires Activation of Matrix Metalloproteinase-9. Stem Cells, 26(5):1231-40, 2008.

87. Salvador, C., Li, B., Hansen, R., Cramer, D., Kong, M., Yan, J.: Yeast-derived b-

Glucan Augments the Therapeutic Efficacy Mediated by Anti-Vascular Endothelial Growth Factor Monoclonal Antibody in Human Carcinoma Xenograft Models. Clinical Cancer Research, 14(4):1239-1247, 2008.

88. Xu, H., * Yan, J., * Huang, YM., Chilton, PM., Ding, CL., Schanie, CL., Wang, L.,

Ildstad ST.: Co-stimulatory blockade of CD154:CD40 in combination with T-cell lymphodepletion results in prevention of allogeneic sensitization. Blood, 111(6):3266-75, 2008. (* two authors contributed equally)

89. *Li, B., Allendorf, D., Hansen, R., Marroquin, J., Cramer, D.E., Harris, C.L., Yan, J.:

Combined Yeast b-Glucan and Anti-tumor mAb Therapy Require C5a-Mediated Neutrophil Chemotaxis via Regulation of Decay Accelerating Factor CD55. Cancer Research. 67(15):7421-7430, 2007.

90. Li B, Cramer D, Wagner S, Hansen R, King C, Kakar S, Ding C, Yan J.: Yeast glucan

particles activate murine resident macrophages to secrete proinflammatory cytokines via MyD88- and Syk kinase-dependent pathways. Clinical Immunology. 124(2):170-81, 2007.

91. Xu H, Chilton PM, Huang Y, Schanie CL, Yan J, Ildstad ST.: Addition of

cyclophosphamide to T-cell depletion-based nonmyeloablative conditioning allows

Yan CV, 2-15-2020

29

donor T-cell engraftment and clonal deletion of alloreactive host T-cells after bone marrow transplantation. Transplantation. 15;83(7):954-63, 2007.

92. Ding C, Yan J.: Regulation of autoreactive B cells: checkpoints and activation. Arch

Immunol Ther Exp (Warsz). 55(2):83-9, 2007.

93. Reca R, Cramer D, Yan J, Laughlin MJ, Janowska-Wieczorek A, Ratajczak J, Ratajczak MZ. : A Novel Role of Complement in Mobilization; Immunodeficient Mice are Poor G-Csf Mobilizers because they Lack Complement-Activating immunoglobulins. Stem Cells. 25(12):3093-100, 2007.

94. Xu H, Yan J, Ildstad ST.: Xenotransplantation: a step closer to reality? (commentary)

Blood. 110:3815, 2007. 95. Yan, J., Gee, RJ., Shlomchik, MJ., Mamula, MJ.: B Cells Drive Early T Cell

Autoimmunity in vivo Prior to Dendritic Cells-mediated Autoantigen Presentation. Journal of Immunology. 177:4481-4487, 2006.

96. Ding C*., Wang L*., Al-Ghawi H., Marroquin J., Mamula M., Yan J.: Toll-like Receptor Engagement Stimulates Anti-snRNP Autoreactive B Cells for Activation. (*co-first author). European Journal of Immunology. 36:2013-2024, 2006.

97. Li, B., Allendorf, D., Hansen, R., Marroquin, J., Ding, C., Cramer, D., and Yan, J.:

Yeast b-Glucan Amplifies Phagocyte Killing of iC3b-opsonized Tumor Cells via CR3-Syk-PI3-kinase Pathway. Journal of Immunology, 177:1661-1669, 2006.

98. *Cramer D., Allendorf D., Baran J., Hansen R., Ratajczak J., Ratajczak M., Yan,

J.: Beta-glucan enhances complement-mediated hematopoietic recovery after bone marrow injury. Blood. 107:835-840, 2006.

99. Ratajczak MZ., Reca R., Wysoczynski M., Yan J., Ratajczak J.: Modulation of the

SDF-1-CXCR4 axis by the third complement component (C3) – Implications for trafficking of CXCR4+ stem cells. Experimental Hematology. 34:986-995, 2006.

100. Reca R, Wysoczynski M, Yan J, Lambris JD, Ratajczak MZ.: The role of

third complement component (C3) in homing of hematopoietic stem/progenitor cells into bone marrow. Adv Exp Med Biol. 586:35-51, 2006.

101. Xu, H., Chilton, P., Tanner, M., Huang, Y., Schanie, C., Dy-Liacco, M.,

Yan, J., Ildstad, ST.: Humoral Immunity is the Dominant Barrier for Allogeneic Bone Marrow Engraftment in Sensitized Recipients. Blood. 108:3611-9, 2006.

102. Yan, J., M. Wolff, J. Unternaehrer, I. Mellman, and M.J. Mamula.: Antigen

directed to CD19 on B cells efficiently activates T cells. Int’l Immunol, 17:869-77, 2005.

Yan CV, 2-15-2020

30

103. Yan, J., Allendorf, DJ., Brandley, B.: Yeast WGP b-Glucan in Conjunction

with Anti-tumor Monoclonal Antibodies to Treat Cancer. Expert Opin Biol Ther. 5:691-702, 2005.

104. Allendorf, DJ., Yan, J., Ross, GD., Hansen, RD., Baran, JT., Subbarao, K.,

Wang, L., Haribabu, B.: C5a-Mediated Leukotriene B4-Amplified Neutrophil Chemotaxis is Essential in Tumor Immunotherapy Facilitated by Anti-Tumor mAb and b-Glucan (Corresponding author) Journal of Immunology. 174:7050-7056, 2005.

105. Hong F., Yan J., Baran J., Allendorf D., Hansen R., Ostroff G., Xing P.,

Cheung N., Ross GD.: Mechanism by which orally administered b(1,3) Glucans enhance the tumoricidal activity of anti-tumor monoclonal antibodies in murine tumor models. Journal of Immunology. 173:797-806, 2004.

106. Liang FT., Yan J., Mbow ML., Sviat SL., Gilmore RD., Mamula M., Fikrig

E.: Borrelia burgdorferi changes its surface antigenic expression in response to immune attack. Infection and Immunity. 72:5759-67, 2004.

107. Hong F., Hansen R., Yan J., Allendorf D., Baran J., Ostroff G., Ross GD.:

b-Glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells. Cancer Research. 63:9023-31, 2003.

108. Anderson B., McNiff J., Yan J., Doyle HA., Mamula MJ., Shlomchik MJ.,

Shlomchik WD.: Memory CD4 T cells do not induce graft-versus-host disease. Journal of Clinical Investigation. 112:101-108, 2003.

109. Wang, T., Scully, E., Yin, Z., Kim H., Wang S., Yan J., Mamula, MJ.,

Anderson JF., Craft, J., and Fikrig E.: IFN-g T cells help control murine West Nile virus infection. Journal of Immunology. 171:2524 – 2531, 2003.

110. Yan, J., and Mamula MJ.: B and T cell tolerance and autoimmunity in

autoantibody transgenic mice. International. Immunology. 14: 963 –971, 2002.

111. Yan, J. and Mamula MJ.: Autoreactive T cell revealed in the normal repertoire: escape from negative selection and peripheral tolerance. Journal of Immunology. 168: 3188-3194, 2002.

112. Doyle HA., J. Yan, B. Liang and M.J. Mamula.: Lupus autoantigens: their

origins, forms, and presentation. Immunological Research. 24: 59-65, 2001.

Yan CV, 2-15-2020

31

113. Yan, J., Vectvika, V., Mayadas, T.N., Ross, G.D.: Critical role of Kupffer cell CR3 in the clearance of soluble b-glucan or C3-opsonized erythrocytes. Immunopharmacology. 46:39-54, 2000.

114. Yan, J., V. Vectvika, Y. Xia, A. Coxon, M.C. Carroll, T.N. Mayadas, and

G.D. Ross.: Soluble b-glucan, a “specific” biological response modifier that targets C3-opsonized tumors in vivo for cytotoxic activation of leukocyte CR3. Journal of Immunology. 163:3045-3052, 1999.

115. Xia Y., Vetvicka V., Yan J., Hanikyrova M., Mayadas T., Ross GD.: The b-

glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells. Journal of Immunology. 162(4): 2281-90, 1999.

116. Ross GD., Vetvicka V., Yan J., Xia Y., Vetvickova J.: Therapeutic

intervention with complement and b-glucan in cancer. Immunopharmacology. 42:61-74, 1999.

117. Yan, J., Ma, B., Guo, X., Sun, Y., Zhang, J., Zhang, H.: CD80 (B7-1)

expression on human tumor cell lines and its costimulatory signals for T cell proliferation and cytokine production. Chin. Med. J. 111:269-71, 1998. PMID: 10374432

118. Zhou, J., Yan, J., and Ma, BL.: The Preparation of Monoclonal Antibody Against

Cell Membrane by Cyclophosphamide. Progress in Microbiology and Immunology. 3:1-3, 2000.

119. Zhou, J., Ma, BL., Yan, J., Zhang, JY., Zhang, HM.: The Production of

Monoclonal Antibody to CD80 by Subtractive Immunization Techniques and Identification of its Biological Activity. Chinese Journal of Immunology. 16(1), 2000.

120. Yan, J., Ma, BL. Effect of Costimulatory Molecule CD80 (B7-1) on T Cell

Activation. Chinese Journal of Immunology. 13(4):196-199, 1997.

121. Yan, J., Ma, B.L., Zhang, JY., Zhang, HM., Wang, S.Y., Sun, Y.: Surface Marker Changes on the Pre- and Post- CD80 (B7-1)-transfected Human Tumor Cell Lines. Chin. J. Tumor Biother. 9:20-24, 1997.

122. Yan, J., Yao, M., Xia, S., Shao, QX., Liu, GZ., Huang, YS., Ma, BL.: Effect of

Lipid Angiogenic Factor on Epidermal Skin Cell Cycle in Wound Healing. Chinese Journal of Biochemical Pharmaceutics. 05, 1997.

Yan CV, 2-15-2020

32

123. Shao, QX, Yan, J., Xia, S.: Effect of Lipid Angiogenic Factor on Cytokine Production by Lymphocytes. Immunological Journal. 04, 1997.

124. Xu, HX., Wang, SJ., Yan, J., Pan, ZC., Xia, S., Liu, GZ.: Isolation and

Characterization of Human Dendritic Cells from Peripheral Blood. Immunological Journal. 03:20-24, 1997.

125. Yan, J., Liu GZ., and Ma, BL.: Current Progress on Gene Therapy for Disease

Treatment. Foreign Medicine: Molecular Biology. 18(2):51-53, 1996.

126. Yan, J., Xia, S., Shao, Q.X.: Extraction and Purification of Lipid Angiogeneic Factor. Chinese Journal of Biochemical Pharmaceutics. 16:2-4, 1996.

127. Yan, J., and Ma, BL. Progress on Costimulatory Molecules CD80 and CD86.

Foreign Medicine: Immunology. 4, 1995.

128. Yan, J., Liu, G.Z., Xu, H.X.: Studies on the Mechanisms Involved in the Dendritic Cell Antigen Presentation. Immunological Journal. 03, 1994.

129. Yan, J., Liu, G.Z., Xu, H.X.: Cytokines Production involved in the Dendritic Cell

Antigen Presentation. J. Zhenjiang Med. Col. 1:1-4, 1994.

130. Yan, J., Yao, K., Zhou, YX.: Molecular Basis of T Cell Activation Signaling Transduction. Foreign Medicine: Immunology. 04, 1993.

131. Yan, J., Yao, K., Zhou, Y.X.: The Relationship Among T Cell Activation,

Activated Signals and IFN-g Production. Immunological Journal. 8(2):95-98, 1992.